Legend Biotech (LEGN) Depreciation & Amortization (CF) (2020 - 2026)
Legend Biotech's (LEGN) quarterly Depreciation & Amortization (CF) came in at $2.4 million in Q1 2026, up 4.35% YoY from $2.3 million in Q1 2025, and up 11.84% on a QoQ basis from $2.1 million in Q3 2025.
Legend Biotech (LEGN) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $2.4 million in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 4.35% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (down 52.21% YoY) and the FY2024 annual result came in at $23.4 million, up 14.22% from the prior year.
- Depreciation & Amortization (CF) grew to $2.4 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.8 million in Q4 2024 to a low of $1.6 million in Q2 2022.
- A 5-year average of $3.0 million and a median of $2.6 million in 2022 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 12505.0% in 2022, down 38.93% in 2022.
- Tracing LEGN's Depreciation & Amortization (CF) over 5 years: stood at $2.5 million in 2022, then soared by 115.68% to $5.4 million in 2023, then rose by 27.0% to $6.8 million in 2024, then slumped by 68.42% to $2.1 million in 2025, then advanced by 11.84% to $2.4 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $2.4 million (Q1 2026), $2.1 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Mn |
| Jun 30, 2026 | 4.00 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Jun 30, 2025 | 2.27 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 6.80 Mn |
| Dec 31, 2024 | 6.80 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Sep 30, 2024 | 2.38 Mn |
| Jun 30, 2024 | 2.78 Mn |
| Jun 30, 2024 | 2.78 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Mar 31, 2024 | 2.80 Mn |
| Dec 31, 2023 | 5.35 Mn |
| Dec 31, 2023 | 5.35 Mn |